摘要
目的：探讨卵巢癌病变中P16抑癌基因的改变和可能的作用机制。方法：应用免疫组化和原位杂交技术检测40例卵巢上皮性癌，12例交界性肿瘤和16例良性肿瘤中的P16表达及其与临床病理的关系；并结合PCNA的改变，进一步了解P16基因在卵巢癌发生，发展过程中可能的病变机制。结果：①在卵巢恶性肿瘤，交界性肿瘤和良性肿瘤中P16蛋白表达阳性率分别为77.5%，41.67%和12.5%，强阳性率依次为65%，16.67%，0 (P<0.001)。P16表达强度与临床分期和生存期有显著相关性(P<0.05)，阳性表达多见于低分化，临床晚期和生存期短的卵巢癌患者。②低分化，临床晚期，生存期短病例组中的PCNA表达高于中﹑高分化，临床早期和生存期长的病例组。③P16和PCNA表达呈正向相关性。④年龄，淋巴结转移，PCNA表达是影响上皮性卵巢癌的预后因素。结论：P16蛋白高表达与卵巢癌进展相关。P16和PCNA的检测可作为判断卵巢癌恶性程度和预测预后的参考指标。
Objective: To explore the alteration and the possible mechanism of tumor suppressor gene P16 in the progression of ovarian carcinoma. Methods: Using immunohistochemical and in situ hybridization techniques. The expression of P16, PCNA and their relationship with clinicopathological parameters were examined in 40 cases of ovarian epithelial cancers, 12 cases of borderline ovarian neoplasms and 16 cases of benign ovarian neoplasms. Results: ①The positive rates of P16 protein among the malignant, borderline and benign ovarian neoplasms were 77.5%, 41.67% and 12.5%. The strong positive rates were 65%, 16.67%, 0, respectively (P<0.001). The expressive rate and intensity of P16 were associated with clinical stages and survival time of patients (P<0.05). P16 protein was positive in most patients of G3, advanced stages or short survival time. ②The PCNA index in G2~G3, advanced stages or short survival time was higher than those in G1, early stages or long survival time. ③There was positive correlation between the expression of P16 and PCNA. ④Age, lymph node metastasis and expression of PCNA were the prognosis factors of ovarian carcinoma. Conclusions: The over-expression of P16 gene may be involved in ovarian epithelial cancer. The detection of P16, PCNA can evaluate the malignant degrees and may predict prognosis of ovarian carcinoma.
引文
1. 糜若然，瞿全新主编. 妇科恶性肿瘤基因诊断与治疗. 第一版. 北京: 人民卫生出版社2001：1
2. Ichikawa Y, Yoshida S, Koyama Y. et al. Inactivation of P16/CDKN2 and P15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer ,1996, 69: 466-470.
3. Ryan A, Jehani RM, Mulligan KT, et al. No evidence exists for methylation inactivation of the P16 tumor suppressor gene in ovarian carcinogenesis. Gynecol Oncol ,1998, 68: 14-17.
4. Fujta M, Enomoto T, Haba T, et al. Alteration of P16 and P15 genes in common epithelial ovarian tumors. Int J Cancer, 1997, 74: 148-155.
5. DongY, Walsh MD, Mcguckin MA, et al. Increased expression of cyclin-dependent kinase inhibitor2 (CDKN2) gene product P16INK4 in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer, 1997,74:57-63.
6. Karin ML, Erika O, Gabriele B, et al. P16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation of mutation in endometrioid and mucinous tumors. Int J Cancer , 1998, 79: 61-65.
7. Serrano M, Hannan GJ, Beach D, et al. A new regulatory morif in cell cyclinD/cdk4 . Nature ,1993, 366: 704-707.
8. Nobori T, Miura K, WU DJ, et al. Deletion of the cyclin dependent Rinase4 inhibitor in multiple human cancers. Nature (Lond), 1994, 368: 753-758.
9. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 1994,79:181-184.
10. Yan Li, Nichols MA, Jerry WS, et al. Transcriptional represion of the D_type cyclin-dependent kinase inhibitor P16 by the retinoblastoma susceptibility gene product PRb. Cancer Res ,1994, 54: 6078-6091.
11. Hunter T. Braking the cycle. Cell , 1993, 75: 839-841.
12. Niederacher D, Yan H-Y, An H-X, et al. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer,1999, 80: 1920-1926.
13. Mccluskey LL, Chen C, Delgadillo E, et al. Differences in P16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol ,1999, 72: 87-92.
14. Dong Y, Walsh MD, Mcguckin MA, et al. Reduced expression of retinoblastoma gene product(PRb)and high expression of P53 are associated with poor prognosis in ovarian cancer. Int J Cancer ,1997, 74: 407-415.
15. Kamb A, Nellere A, Jane WF, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 1994, 264: 436-441.
16. Reed A, Califano J, Cairns P, et al. High frequency of P16 (CDKN2/MTS-1/INK4A) I -nactivation in head and neck squamous cell carcinoma. Cancer Res, 1996,56:3630-3633.
17. Shigemasa K, Hu C, West CM, et al. P16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Invest, 1997, 4: 95-102.
Sui L, Dong Y, Ohno M, et al. Inverse expression of CDk4 and P16 in epithelial
18. ovarian tumors. Gynecol Oncol, 2000, 79: 230-237.
19. Hall P, Levison D, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990, 162:285-294.
20. Thomas H, Nasim MM, Sarraf CE, et al. Proliferation cell nuclear antigen (PCNA) immunostaining a prognostic factor in ovarian cancer. Br J Cancer, 1995,71:357-362.
21. Gao L, Wilkinson N, Hale R, et al. Ovarian epithelial tumors: expression of PCNA. J Pathol, 1992: 168(supple): 134-138.
22. Tahan S, Neuberg D, Dieffenbach A, et al. Prediction of early relapse and shortened suvival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer, 1993, 71: 3552-3559.
23. Kusume T, Tsuda H, Kwabata M, et al. The P16-cyclinD1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res, 1999, 5: 4152-4157.
24. 王刚, 王世阆, 王靖华, 等. 细胞周期调节通路P16-cyclin-PRb与人卵巢浆液性囊腺癌的相关性研究. 实用妇产科杂志, 2002,18:101-103.
25. Rodabugh KJ, Biggs RB, Oureshi TA, et al. Detailed detection mapping of chromosome 9P and P16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene, 1995,11:1249-1254.
26. Shin YC, Kerr J, Liu J, et al. Rare mutation and no hypermethylation at the CDKN2A locus in epithelial ovarian tumors. Int J Cancer, 1997,70:508-511.
27. Duro D, Bernard O, Valle VD, et al. Inactivation of P16INK4/MTS1 gene by a chromosome translocation t (9; 14) (p21-22; q11) in all of B-cell type. Cancer Res, 1996,56:848-854.